Collegium Pharmaceutical (COLL) Non-Current Debt (2014 - 2026)

Collegium Pharmaceutical's Non-Current Debt history runs 13 years deep, the most recent figure standing at $531.7 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 0.74% year-over-year to $531.7 million; the TTM figure through Mar 2026 stood at $531.7 million (down 0.74% YoY), while the FY2025 annual figure was $542.1 million, down 1.57% from the prior year.
• Non-Current Debt was $531.7 million for Q1 2026 at Collegium Pharmaceutical, down from $542.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $565.7 million in Q3 2024 to a low of $132.8 million in Q2 2024.
• Historically, Non-Current Debt has averaged $415.6 million across 5 years, with a median of $484.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt surged 544.73% in 2022, then slumped 57.13% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $397.6 million in 2022, then slumped by 44.23% to $221.7 million in 2023, then jumped by 148.4% to $550.7 million in 2024, then decreased by 1.57% to $542.1 million in 2025, then decreased by 1.92% to $531.7 million in 2026.
• The last three Non-Current Debt figures came in at $531.7 million (Q1 2026), $542.1 million (Q4 2025), and $505.6 million (Q3 2025), per Business Quant data.